

For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

ROGER JEFFS, Ph.D.
ADOPTS 10b5-1 TRADING PLAN

Silver Spring, MD, November 11, 2003: United Therapeutics Corporation (NASDAQ: UTHR) announced today that Dr. Roger Jeffs, President and Chief Operating Officer, has adopted a prearranged trading plan in accordance with Securities and Exchange Commission Rule 10b5-1 and United Therapeutics' Securities Trades by Company Personnel Policy.

Rule 10b5-1 of the Securities Exchange Act of 1934 permits officers and directors of public companies to adopt predetermined written plans for trading specified amounts of company stock when they are not in possession of material nonpublic information in order to gradually diversify their investment portfolio, to minimize the market effect of stock sales by spreading them out over an extended period of time, and to avoid concerns about initiating stock transactions while in possession of material nonpublic information.

The 10b5-1 plan adopted by Dr. Jeffs involves an order to sell a total of 100,000 shares of United Therapeutics common stock that will be issued as a result of the exercise of certain stock options. The prearranged sale will take place in increments of 3,500 shares approximately every two weeks beginning on November 20, 2003 and no sale will occur at a price below \$20.00 per share. Dr. Jeffs' 10b5-1 plan will expire on the first to occur of the date 100,000 shares have been sold or December 16, 2005.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.